NCT06147388 Regression of Cervical Precancerous Lesions and Associated Risk Factors
| NCT ID | NCT06147388 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General University Hospital, Prague |
| Condition | Cervix Uteri SIL |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-09-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.
Eligibility Criteria
Inclusion Criteria: 1. squamocolumnar junction fully visualized 2. bioptically verified CIN 2 or CIN 3 3. age ≥ 18 years 4. age ≤ 40 years 5. informed consent Exclusion Criteria: 1. squamocolumnar junction not fully visualized 2. suspicion on glandular lesion 3. suspicion on invasive cancer 4. personal history of CIN 2, 3 or cerv. cancer 5. gravidity 6. HIV positivity 7. immunosuppression 8. impossible photographic documentation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06147388 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Cervix Uteri SIL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06147388 currently recruiting?
Yes, NCT06147388 is actively recruiting participants. Contact the research team at lukas.dostalek@vfn.cz for enrollment information.
Where is the NCT06147388 trial being conducted?
This trial is being conducted at Prague, Czechia.
Who is sponsoring the NCT06147388 clinical trial?
NCT06147388 is sponsored by General University Hospital, Prague. The trial plans to enroll 300 participants.